Идёт набор NCT07421700

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Фаза I / Фаза II С лечением Urothelial Cancer Advanced/Metastatic Urothelial Cancer Urothelial Carcinoma

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: PF-08634404, Enfortumab Vedotin.
Кому может быть актуально: Состояния в реестре: Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: США, Австралия, Китай, Япония, Пуэрто-Рико +1
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

AN INTERVENTIONAL PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, ANTITUMOR ACTIVITY, AND PHARMACOKINETICS OF PF 08634404 MONOTHERAPY OR IN COMBINATION WITH ENFORTUMAB VEDOTIN IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER

Обзор

This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissues or other parts of the body. The purpose of the study is to see if PF-08634404 is safe, how well it works, how it moves through the body, and how it affects the cancer. The study will also look at how the medicine may change certain markers in the body that are linked to cancer. To join the study, participants must: * Be adults (18 years or older) and * Have locally advanced or metastatic urothelial cancer, The study has two groups: * Cohort A: People who have already received treatment for their cancer will get the study medicine ( PF-08634404) alone. * Cohort B: People who have not had treatment before will get the study medicine along with another cancer medicine called enfortumab vedotin. Everyone in the study will get the study medicine through a vein (IV infusion) with or without enfortumab vedotin. Treatment will continue as long as it helps and side effects are manageable. Before starting, participants will go through a screening period to check if they are eligible. During the study, they will have regular visits for treatment, health checks, and tests to see how the cancer is responding. Scans will be done regularly to monitor the cancer. If the cancer gets worse but the treatment is still helping and side effects are manageable, participants may be allowed to continue treatment with their doctor's and the sponsor's agreement.

Вмешательства

Биопрепарат PF-08634404
Concentrate for solution for Infusion.
Биопрепарат Enfortumab Vedotin
Powder for concentrate for solution for infusion

Первичные конечные точки

Confirmed Objective Response Rate (ORR) by investigator [Срок оценки: Up to approximately 3 years]
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [Срок оценки: Through 90 days after the last study intervention; Up to approximately 3 years]
Number of participants with dose limiting toxicity (DLT) in Part 1 of Cohort B [Срок оценки: Through 90 days after the last study intervention; Up to approximately 3 years]

Вторичные конечные точки (6)

Duration of Response (DOR) per RECIST v1.1 by investigator [Срок оценки: Up to approximately 3 years]
Progression Free Survival (PFS) per RECIST v1.1 by investigator [Срок оценки: Up to approximately 3 years]
Overall Survival (OS) [Срок оценки: Up to approximately 3 years]
Number of Participants With Clinical Laboratory Abnormalities [Срок оценки: Through 90 days after the last study intervention; Up to approximately 3 years]
Pharmacokinetics (PK): Serum concentration of PF-08634404 [Срок оценки: Up to 37 days after the last dose of treatment]
Incidence of Anti-Drug Antibody (ADA) against PF-08634404 [Срок оценки: Up to 37 days after the last dose of treatment]

Критерии участия

Критерии включения

Age ≥18 years at the time of screening.
Histologically confirmed locally advanced or metastatic urothelial carcinoma (LA/mUC).
Measurable disease per RECIST v1.1 criteria.
ECOG performance status of 0 or 1.
Adequate organ function, including hematologic, hepatic, and renal parameters.
Willingness to comply with study procedures and provide informed consent.
For participants of childbearing potential: agreement to use effective contraception during the study and for a defined period after the last dose.

Критерии исключения

Participants will be excluded if they meet any of the following:

History of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy
Known active CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression
Active autoimmune diseases requiring systemic treatment within the past 2 years
Participation in another investigational study within 30 days or 5 half-lives of the investigational product.
Pregnant or breastfeeding individuals.
Inability or unwillingness to comply with study requirements.
Study staff or their immediate family members directly involved in the conduct of the study.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение: Нерандомизированное
Модель: Последовательный дизайн
Маскирование: Открытое
Основная цель: Лечение